BofA Securities analyst Geoff Meacham reiterated a Neutral rating and $200.00 price target on Moderna (NASDAQ: MRNA) after attending the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE